Study Demonstrates Feasibility of Hologram Technology in Liver Tumor Ablation
June 14, 2020—Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to research presented during a virtual session of the Society of Interventional Radiology's (SIR) 2020 annual scientific meeting held June 13-14.
Transarterial Chemoperfusion Studied for Treating Mesothelioma
June 14, 2020—The Society of Interventional Radiology (SIR) announced the presentation of research showing that transarterial chemoperfusion as a treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options.
Guerbet's Lipiodol Ultra-Fluid Approved in China for cTACE
June 9, 2020—Guerbet announced that the China National Medical Products Administration has approved an additional indication for Lipiodol Ultra-Fluid for use in conventional transarterial chemoembolization (cTACE) for adult patients with intermediate-stage hepatocellular carcinoma (HCC) in the People's Republic of China.
Sirtex Medical Appoints Dr. Mark Turco as Global Chief Medical Officer
June 3, 2020––Sirtex Medical US Holdings, Inc. announced the appointment of Mark A. Turco, MD, as Global Chief Medical Officer and Executive Vice President of Research & Development, effective June 1, 2020. Sirtex is focused on targeted radiation therapies for liver cancer, including SIR-Spheres yttrium-90 resin microspheres. The company has global headquarters in Woburn, Massachusetts.
Yttrium-90 Radioembolization Analyzed in Patients With Intrahepatic Cholangiocarcinoma
May 28, 2020—In Journal of Vascular and Interventional Radiology (JVIR), Stefan Buettner, MD, et al reported observational data of treatment outcomes of yttrium-90 (Y-90) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma.
Austrian Study Supports Simultaneous Stereotactic RF Ablation to Manage Multiple Liver Tumors
May 20, 2020—Simultaneous stereotactic radiofrequency ablation (SRFA) was shown to be a “feasible, safe, and efficacious option” for the simultaneous management of multiple primary and metastatic liver tumors in a study by Peter Schullian, MD, et al published in the June edition of Journal of Vascular and Interventional Radiology (JVIR; 2020;31:943–952).
Guerbet’s Vectorio Kit Approved in Canada for Interventional Oncology Procedures
May 19, 2020—Guerbet announced the registration in Canada of Vectorio, a kit for imaging of hepatocellular carcinoma (HCC) that provides a set of Lipiodol (Guerbet)-resistant medical devices, including patented syringes, stopcock, and sampling devices.
Study Suggests Need for Cautious Patient Selection to Treat HCC With Y-90 Radioembolization
May 1, 2020—Findings from an evaluation of yttrium-90 (Y-90) radioembolization outcomes across Child-Pugh scores in patients with advanced hepatocellular carcinoma (HCC), per the Barcelona Clinic Liver Cancer (BCLC) staging system, were published by Qingquan Zu, MD, et al in CardioVascular and Interventional Radiology (CVIR; 2020;43:721–731).
Terumo's Biodegradable Drug-Eluting BioPearl Microspheres Receive CE Mark Approval
April 28, 2020—Terumo Europe NV announced that the company's BioPearl microspheres has received European CE Mark approval as an option for patients eligible for locoregional embolization of target artery blood supply to liver cancer.
IceCure Continues Global Expansion of ProSense Cryoablation System With Approval in India
April 28, 2020—IceCure Medical announced regulatory approval in India for the sale and marketing of the company’s next-generation, liquid nitrogen–based ProSense system and associated products for the destruction of benign and cancerous tumors by cryoablation in extensive indications, including breast, lung, bone, kidney cancer, and more.
Lipiodol Evaluated as an Imaging Biomarker of Tumor Response After cTACE
April 16, 2020—Findings from a single-center, single-arm study support the use of Lipiodol (Guerbet LLC) as an imaging biomarker of tumor response after conventional transarterial chemoembolization (cTACE) for both primary and secondary liver cancer.
SIR Issues Clinical Notification on Aerosol-Generating Procedures
March 27, 2020—The Society of Interventional Radiology (SIR) has issued a clinical notification to provide medical decision-making guidance on how to perform aerosol-generating procedures (AGP) safely in the interventional radiology suite.
Varian to Acquire Oncozene and Embozene Embolic Bead Lines From Boston Scientific
July 2, 2019—Varian Medical Systems, Inc. continued to expand its interventional oncology/embolic portfolio, announcing plans to acquire Boston Scientific's drug-loadable microsphere and bland embolic bead product lines for treating arteriovenous malformations and hypervascular tumors.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.